Gilead Sciences top products by revenue 2020-2022

This statistic shows the top products of biopharmaceutical company Gilead Sciences from 2020 to 2022, based on revenue. Gilead Sciences Inc. is headquartered in California and is specialized in discovering, developing and commercializing therapeutics. In 2022, Gilead Sciences' COVID-19 treatment Veklury (remdesivir) generated some 3.9 billion U.S. dollars in revenue, a significant decrease compared to 5.6 billion in 2021.

Leading products of Gilead Sciences from 2020 to 2022 based on revenue (in million U.S. dollars)

Characteristic	2020	2021	2022
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

February 2023

More information

Region

Worldwide

Survey time period

2020 to 2022

Special properties

Supplementary notes

* Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.
** Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

Open this statistic in...

Spanish

Citation formats